Clinical Trials Browser

OTHER × lirilumab × 1 year × Clear all

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT03341936 2025-06-18

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Phase 2 Active not recruiting

29 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell